Evaluating spending and regulation decisions on the basis of objective criteria is a good thing. The standard tool in economics to do so in called Cost-Benefit Analysis. In a high quality, just-released report, Multiple Sclerosis NZ argues, with great lucidity, that Pharmac is not taking into account all costs & benefits on society when it decides which drugs to fund.
